Conference abstractPublished 26 Oct 2015
2015: A decisive year for the Mexican biosimilars industry
Tecnologico de Monterrey, Mexico
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Biopharmaceuticals represent a very promising option for treating the most challenging diseases; nevertheless, there is no budget in the world that could effectively provide universal healthcare with a purely innovative drugs portfolio.Biosimilars represent a lower cost alternative for public healthcare systems. For instance, subsequent versions of recombinant erythropoietin with price reductions of up to 90% were launched in Mexico in 2006, and 82% cheaper rituximab versions entered the market later, among many others. Such products were originally registered as traditional generics in Mexico, but now that the regulatory framework for biosimilars is complete and well established by the Official Norm NOM-257-SSA1-2014issued in December 2014, local manufacturers face a great challenge. They need to perform some or most of the required studies for demonstrating their products’ safety, quality and biocomparability within eight months in order to renew their sanitary registration. Unfortunately, some of them cannot be fully done in Mexico due to lack of R&D infrastructure. Therefore, the biosimilars industry is at a crucial time in the country now that the Government is eager to have low-cost medicinesbut at the same time has developed more strict regulations for them. This all represents many business opportunities for laboratories, distributors and biotech companies who are willing to make quality their competitive advantage, as well as the possibility for patients to haveimproved access to safer and more efficacious treatments.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- BylineArticles whose byline prints “Ricardo Ibarra-Cabrera”
